Table 3.
Disease and treatment characteristics of patients who are alive (n=9)
| Initial Stage | Study | First relapse site | Time to first relapse (months) | Time to brain metastases (months) | Surgery | Brain irradiation | Chemotherapy | BMT | Last follow-up from brain relapse (months) |
|---|---|---|---|---|---|---|---|---|---|
| I | 3 | Lung | 8 | 13 | No | 3000 cGy | CDDP/CPM x 2 years | No | 381 |
| I | 4 | Lung | 9 | 25 | PR | 3000 cGy | VP16/carbo X 3 cycles, then VCR/CPMX 2 cycles | No | 237 |
| II | 5 | Lung | 6 | 23 | PR | 2400 cGy + 600cGy boost | VP16/carbo X 9 courses | No | 35 |
| II | 5 | Lung, abdomen | 8 | 17 | Biopsy only | 1080cGy + 1080 c Gy boost | VCR, ifosfamide, carbo, VP16 X 2 cycles/carbo, VP16 X 4 cycles | No | 109 |
| III | 5 | Lung | 15 | 37 | Biopsy only | 2000 cGy | Ifosfamide, VP16 | No | 140 |
| III | 5 | Brain, spinal cord | 28 | 28 | Biopsy only | Craniospinal 4080 cGy | CPM/VP16 alternating with Carbo/VP16 x 5 months | Yes (melphalan/thiotepa) | 199 |
| IV (lung) | 5 | Brain | 8 | 8 | GTR | 1980 cGy + 1000 cGy boost | No | No | 186 |
| IV (lung) | 5 | Brain | 7 | 7 | GTR | 3060 cGy | CPM, VP16 alternating with carbo, VP16 | No | 44 |
| IV (lung) | 5 | Brain, lung, heart | 3 | 3 | Biopsy only | Dose not known | VP16, CPM X 2 cycles | Yes (busulphan/melphalan) | 121 |
PR, partial resection; GTR, gross total resection; CDDP, cisplatin; CPM, cyclophosphamide; VP16, etoposide; VCR, vincristine; Carbo, carboplatin.